The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Challenges and opportunities in NASH drug development
Abstract
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical need, as no licensed drugs have been approved thus far. Currently, histopathological assessment of liver biopsies is mandatory as a primary endpoint for conditional drug approval. This requirement represents one of the main challenges in the field, as there is substantial variability in this invasive histopathological assessment, which leads to dramatically high screen-failure rates in clinical trials. Over the past decades, several non-invasive tests have been developed to correlate with liver histology and, eventually, outcomes to assess disease severity and longitudinal changes non-invasively. However, further data are needed to ensure their endorsement by regulatory authorities as alternatives to histological endpoints in phase 3 trials. This Review describes the challenges of drug development in NAFLD-NASH trials and potential mitigating strategies to move the field forward.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current liver-directed therapies include inhibitors of lipogenesis whose targets include fatty acid synthase, diacyl glycerol transferase (DGAT), ACC, broad metabolic modulators including thyroid hormone beta (THRβ) agonists, agonists of GLP-1R, PPARs and gastric inhibitory polypeptide receptor (GIPR), as well as a fatty acid-bile acid conjugate (Aramchol) and FGF21, among others (307).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [307]
In the citing paper
“Each of these use-cases imposes different challenges and requirements for validation requested by regulatory agencies (307).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [307]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 1×
“In the liver, fatty acids follow one of three disposal pathways: (1) they are used as an energy source through β-oxidation in the mitochondria, (2) they are esterified into triglycerides and stored as hepatic lipid droplets, and 3) they are released as VLDL in the systemic circulation.”
BackgroundChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Research works printed but not linked: 6
- Noureddin, M. & Rinella, M. E. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin. Liver Dis. 19, 361–379 (2015).
- Björnsson, E. S. Incidence and outcomes of DILI in Western patients. Clin. Liver Dis. 4, 9–11 (2014).
- Guo, T. A tool to help you decide (detect potentially serious liver injury). In Annual Conference of the American Association for the Study of Liver Diseases (AASLD, 2008).
- Guo, T. How a SAS/IntrNet tool was created at the FDA for the detection of potential drug-induced liver injury using data with CDISC standard. In Western Users of SAS Software Annual Conference (WUSS, 2009).
- Pokkalla, H. et al. Machine learning models accurately interpret liver histology in patients with nonalcoholic steatohepatitis (NASH). Hepatology 70, 121A–122A (2019).
- Alkhouri, N. & McCullough, A. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol. Hepatol. 8, 661–668 (2012).
Cited by
Israelsen, M., Francque, S., Tsochatzis, E. A., & Krag, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 348
Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
Nie, Q., Luo, X., Wang, K., Ding, Y., Jia, S., Zhao, Q., Li, M., Zhang, J., Zhuo, Y., Lin, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.034 · Cited by 326
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
“548 The properties of chemical absorption, distribution, metabolism, excretion, and toxicity differ between species, resulting in drug doses that are bene fi cial and non-toxic in mice showing insuf fi cient ef fi cacy or causing side effects in humans.”
Updated mechanisms of MASLD pathogenesis
Li, Y., Yang, P., Ye, J., Xu, Q., Wu, J., & Wang, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02108-x · Cited by 300
“At present, no licensed pharmacological therapy has been approved for the treatment of MASLD, and drug development in MASLD trials remains challenging due to the high variability in histopathological assessment of liver biopsies [134].”
BackgroundLiver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Metadata
- Authors
- Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N.
- Affiliations
- University of Oxford (GB)
- Mayo Clinic (US)
- Houston Methodist (US)
- Arizona Liver Health (US)
- Corresponding author
- Harrison, Stephen A.
- Venue
- Nature Medicine
- Published
- 2023-03
- Volume
- 29
- Issue
- 3
- Pages
- 562-573
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4323670059
- Cited by
- 353
- References
- 125
- Citations by year
- 2026: 70 · 2025: 112 · 2024: 130 · 2023: 41
- FWCI
- 13.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, histopathological assessment, liver biopsy, non-invasive tests, biomarkers, clinical trial endpoints, screen failure, trial design, disease severity assessment
- MeSH terms
- Drug Development, Humans, Liver, Liver Cirrhosis, Severity of Illness Index, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenges and opportunities in NASH drug development. https://app.cochat.ai/papers/10.1038/s41591-023-02242-6
- The paper
- Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023). Challenges and opportunities in NASH drug development. Nature Medicine. https://doi.org/10.1038/s41591-023-02242-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.